{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:30:26Z","timestamp":1762867826028,"version":"3.40.5"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"AHERF"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>In India, many centers use infliximab at lower doses of 3\u20105\u00a0mg\/kg without the loading dose for spondyloarthritis (SpA) patients. It is then continued on an as\u2010required basis, rather than a fixed schedule. Our study was undertaken to see if the trough drug levels and anti\u2010drug antibodies in patients with SpA treated with as\u2010needed infliximab dosing correlated with the disease activity measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty\u2010five adult SpA patients in the age group 18\u201070\u00a0years were recruited. They had received three or more infusions of infliximab at 3\u20105\u00a0mg\/kg over the past 6 to 12\u00a0months. Patient's serum tumor necrosis factor\u2010\u03b1, trough infliximab levels and anti\u2010drug antibodies were measured by enzyme\u2010linked immunosorbent assay technique. The disease activity was quantified by Ankylosing Spondylitis Disease Activity Score \u2013 erythrocyte sedimentation rate\/ C\u2010reactive protein (ASDAS\u2010ESR\/CRP) scores. Correlation between quantitative variables was analyzed by the Spearman's correlation assay. The difference in mean trough infliximab and ASDAS between the drug antibody positive and negative patients was assessed using the Mann\u2010Whitney <jats:italic>U<\/jats:italic> test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was a significant negative correlation between the trough infliximab levels and the ASDAS\u2010ESR (rs = \u22120.57, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01) and ASDAS\u2010CRP scores (<jats:italic>r<\/jats:italic>s\u00a0=\u00a0\u22120.53, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01). Anti\u2010drug antibodies were positive in 68.7% of the patients and in comparison to the antibody negative patients, had significantly higher ASDAS\u2010ESR and ASDAS\u2010CRP scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Spondyloarthritis patients on low\u2010dose, as\u2010needed infliximab therapy, have both the trough infliximab and anti\u2010drug antibodies correlate significantly with the measures of disease activity. We hypothesize that trough infliximab levels and anti\u2010drug antibodies may be used to predict a suboptimal response due to secondary resistance in SpA patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13636","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T13:28:58Z","timestamp":1560864538000},"page":"1638-1643","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti\u2010drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as\u2010needed infliximab treatment"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0128-9913","authenticated-orcid":false,"given":"Abhishek","family":"Patil","sequence":"first","affiliation":[{"name":"Department of Rheumatology Indraprastha Apollo Hospitals Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundeep","family":"Upadhyaya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Indraprastha Apollo Hospitals Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reetika","family":"Dawar","sequence":"additional","affiliation":[{"name":"Department of Microbiology Indraprastha Apollo Hospitals Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikunjkumar","family":"Dadhaniya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Indraprastha Apollo Hospitals Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isha","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Indraprastha Apollo Hospitals Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirinder J.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Indraprastha Apollo Hospitals Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-4170","authenticated-orcid":false,"given":"Rohini","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Indraprastha Apollo Hospitals Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_9_2_1","DOI":"10.1093\/rheumatology\/41.11.1280"},{"doi-asserted-by":"publisher","key":"e_1_2_9_3_1","DOI":"10.2217\/imt.15.28"},{"doi-asserted-by":"publisher","key":"e_1_2_9_4_1","DOI":"10.1016\/j.semarthrit.2017.04.005"},{"doi-asserted-by":"publisher","key":"e_1_2_9_5_1","DOI":"10.1136\/annrheumdis-2011-200828"},{"doi-asserted-by":"publisher","key":"e_1_2_9_6_1","DOI":"10.1016\/j.crohns.2014.01.009"},{"doi-asserted-by":"publisher","key":"e_1_2_9_7_1","DOI":"10.1136\/ard.2008.092833"},{"doi-asserted-by":"publisher","key":"e_1_2_9_8_1","DOI":"10.1007\/s00535-013-0829-7"},{"doi-asserted-by":"publisher","key":"e_1_2_9_9_1","DOI":"10.1136\/ard.2009.108233"},{"doi-asserted-by":"publisher","key":"e_1_2_9_10_1","DOI":"10.1136\/ard.2010.133645"},{"doi-asserted-by":"publisher","key":"e_1_2_9_11_1","DOI":"10.1136\/ard.2008.094870"},{"doi-asserted-by":"publisher","key":"e_1_2_9_12_1","DOI":"10.1111\/j.1479-8077.2006.00188.x"},{"doi-asserted-by":"publisher","key":"e_1_2_9_13_1","DOI":"10.1016\/j.rdc.2012.09.003"},{"doi-asserted-by":"publisher","key":"e_1_2_9_14_1","DOI":"10.1016\/j.intimp.2014.04.006"},{"doi-asserted-by":"publisher","key":"e_1_2_9_15_1","DOI":"10.1016\/j.jaad.2006.07.017"},{"doi-asserted-by":"publisher","key":"e_1_2_9_16_1","DOI":"10.1016\/j.cgh.2006.06.025"},{"issue":"9","key":"e_1_2_9_17_1","first-page":"14","article-title":"Analytical and clinical evaluation of an immunoassay for estimating immunogenicity of infliximab and etanercept in indian population","volume":"64","author":"Ghia C","year":"2016","journal-title":"J Assoc Physicians India"},{"doi-asserted-by":"publisher","key":"e_1_2_9_18_1","DOI":"10.1136\/annrheumdis-2012-202545"},{"doi-asserted-by":"publisher","key":"e_1_2_9_19_1","DOI":"10.1093\/rheumatology\/ker124"},{"doi-asserted-by":"publisher","key":"e_1_2_9_20_1","DOI":"10.1056\/NEJMoa020888"},{"doi-asserted-by":"publisher","key":"e_1_2_9_21_1","DOI":"10.1002\/art.22214"},{"doi-asserted-by":"publisher","key":"e_1_2_9_22_1","DOI":"10.2147\/BTT.S96982"},{"doi-asserted-by":"publisher","key":"e_1_2_9_23_1","DOI":"10.1136\/annrheumdis-2016-210770"},{"doi-asserted-by":"publisher","key":"e_1_2_9_24_1","DOI":"10.1007\/s00296-016-3428-0"},{"doi-asserted-by":"publisher","key":"e_1_2_9_25_1","DOI":"10.1371\/journal.pone.0144900"},{"doi-asserted-by":"publisher","key":"e_1_2_9_26_1","DOI":"10.1111\/j.1346-8138.2012.01679.x"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13636","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T17:31:57Z","timestamp":1694280717000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/1756-185X.13636"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13636","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"type":"print","value":"1756-1841"},{"type":"electronic","value":"1756-185X"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"2018-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}